A Single-Cell Pan-Cancer Platelet Atlas Reveals MHC-I Reprogramming and Prognosis

Authors:
  • JHJianxiang Huang
    Jianxiang Huang
  • ZZZhiran Zhai
    Zhiran Zhai
  • WZWanrong Zong
    Wanrong Zong
  • LBLongbo Bai
    Longbo Bai
  • XCXingyu Chen
    Xingyu Chen
  • ZWZheng Wu
    Zheng Wu
  • JQJiayue Qiu
    Jiayue Qiu
  • ELEr Li
    Er Li
  • JLJianan Li
    Jianan Li
  • KCKai-Yue Cao
    Kai-Yue Cao

Abstract
Platelets provide minimally invasive readouts of cancer biology, yet tumor-induced systemic platelet states remain poorly resolved. Here, we integrated 88 single-cell RNA-sequencing datasets across 24 cancer types and 14 non-cancer diseases to construct a pan-cancer atlas of the hematopoietic stem cell–megakaryocyte–platelet continuum. Among ~60,000 platelets, tumor-enriched subsets displayed a distinct MHC class I-high activation program, enhanced coagulation signatures, and lineage links to reprogrammed megakaryocyte precursors. This program was converted into an MHC class I gene expression index (MGEI) that detected pathological reprogramming across 10 cohorts, validated in an orthotopic lung cancer mouse model. We further derived a core marker-based platelet activation status (PAS) that stratified survival across cohorts and linked platelet activity with multi-omics and H&E histopathological architecture in TCGA-NSCLC. Together, these complementary thromboimmune biomarkers provide a translational framework for platelet-informed risk stratification and precision oncology.